The PCSK9 Competitive Grant Program, an independently-reviewed competitive grant program supported by Amgen, is accepting proposals for novel research aimed at advancing the understanding of PCSK9 and atherosclerosis.

This global program will provide individual grants of up to $200,000 to established and junior investigators (within five years of completion of training). The deadline for applications is Friday, May 11, 2018 (11:59 p.m. PT).

More information on the scope of proposals, additional qualifications, the review process and the application are available on the program website.